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Abstract Upon antigen stimulation, T lymphocytes undergo dramatic changes in metabolism to
fulfill the bioenergetic, biosynthetic and redox demands of proliferation and differentiation.
Glutathione (GSH) plays an essential role in controlling redox balance and cell fate. While GSH can
be recycled from Glutathione disulfide (GSSG), the inhibition of this recycling pathway does not
impact GSH content and murine T cell fate. By contrast, the inhibition of the de novo synthesis of
GSH, by deleting either the catalytic (Gclc) or the modifier (Gclm) subunit of glutamate–cysteine
ligase (Gcl), dampens intracellular GSH, increases ROS, and impact T cell differentiation. Moreover,
the inhibition of GSH de novo synthesis dampened the pathological progression of experimental
autoimmune encephalomyelitis (EAE). We further reveal that glutamine provides essential
precursors for GSH biosynthesis. Our findings suggest that glutamine catabolism fuels de novo
synthesis of GSH and directs the lineage choice in T cells.
DOI: https://doi.org/10.7554/eLife.36158.001
Introduction
Glutathione (GSH) is the most abundant antioxidant capable of providing reducing equivalents and
it also serves as a versatile nucleophilic cofactor in a wide spectrum of metabolic reactions in aerobic
organisms (Kosower and Kosower, 1978; Meister, 1982). While some cells are capable of
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employing extracellular GSH, the utilization of extracellular GSH plays a minor role in regulating
GSH homeostasis, since the extracellular levels of GSH are normally three orders of magnitude lower
than intracellular GSH concentrations, which are usually in the millimolar range (Kosower and
Kosower, 1978; Meister, 1982; Perrone et al., 2005; Hwang et al., 1992; Ganguly et al., 2003;
Bennett et al., 2009; Morgan et al., 2011; Park et al., 2016). Hence, cellular GSH content is largely
determined by intracellular production through de novo synthesis, a process mediated by two ATP-
dependent ligases, glutamate-cysteine ligase (GCL) and glutathione synthase (GS), as well as
through regeneration of GSH from GSSG, a process catalyzed by glutathione disulfide reductase
(GSR) (Meister, 1982; Lu, 2009). In the process of de novo synthesis, GCL, a heterodimer of a cata-
lytic subunit (GCLC) and a modifier subunit (GCLM), catalyzes the first and rate-limiting step to form
the dipeptide g-glutamylcysteine (g-GC) from cysteine and glutamate (Franklin et al., 2009;
Chen et al., 2005). After the initial step, GS catalyzes the formation of GSH by ligating g-GC with
glycine. As such, GSH synthesis is determined by the availability of its constituent amino acids, cyste-
ine, glycine and glutamate, which intersects with glucose and glutamine metabolic pathways and
reflects the overall metabolic status in the cell. In particular, glutamine catabolism may coordinate
with de novo GSH synthesis by promoting cysteine uptake and providing glutamate, an immediate
product of glutamine after deamination (Altman et al., 2016; Hensley et al., 2013; Gorrini et al.,
2013). However, it remains unknown the extent to which de novo synthesis versus recycling of GSSG
contributes to GSH homeostasis in T cells and how the perturbation of GSH homeostasis impacts T
cell differentiation.
The regulation of metabolic pathways is tightly linked with T cell activation, differentiation, and
immune functions (Wang and Green, 2012; Pearce and Pearce, 2013; O’Neill et al., 2016;
Patel and Powell, 2017; Ma et al., 2017; Buck et al., 2017; Zeng and Chi, 2017; Finlay and Can-
trell, 2011; Weinberg et al., 2015). We and others have shown that activation of T cells leads to a
significant enhancement of aerobic glycolysis but a suppression of mitochondria-dependent fatty
acid oxidation (FAO) (Wang et al., 2011; Frauwirth et al., 2002; Jacobs et al., 2008; Shi et al.,
2011). Following the initial growth stage of T cell activation, FAO fuels and drives induced CD4+
regulatory T (Treg) cell differentiation (Shi et al., 2011; Michalek et al., 2011). In contrast, a persis-
tent glycolytic program is engaged not only during the initial growth phase of T cell activation but
also throughout the differentiation of other CD4+T helper (TH) cells and CD8
+ cytotoxic T (CTL) cells
(Shi et al., 2011; Michalek et al., 2011; Finlay et al., 2012). However, oxygen consumption is also
dramatically elevated in active T cells since heightened glutamine catabolism via mitochondria-
dependent oxidation following T cell activation fuels oxidative phosphorylation (OXPHOS) by provid-
ing a-ketoglutarate (a-KG), an anaplerotic substrate of the tricarboxylic acid cycle (TCA cycle)
(Wang et al., 2011; Sena et al., 2013; Kamin´ski et al., 2012). OXPHOS in mitochondria generates
ATP through the electron transport chain (ETC) and also produces reactive oxygen species (ROS) as
byproducts, rendering mitochondria a major source of intracellular ROS. Superoxide anion (O2
.
 ),
the ‘primary’ ROS derived from mitochondrial ETC, is converted to hydrogen peroxide (H2O2) by
spontaneous and enzymatic processes, whereupon H2O2 freely diffuses into cytosol and functions as
a redox signaling molecule to elicit a diverse array of cellular responses, the spectrum of which
depends on the level of ROS (Sena et al., 2013; Kamin´ski et al., 2012; Murphy, 2009;
Schieber and Chandel, 2014). A fine-tuned balance between ROS generation and antioxidant
capacity ensures physiological levels of intracellular ROS, which are required for driving essential sig-
naling events to support T cell-mediated immune responses (Weinberg et al., 2015; Murphy and
Siegel, 2013; Kamin´ski et al., 2013; Simeoni et al., 2016; Rashida Gnanaprakasam et al., 2018).
Accordingly, oxidative stress, occurring when ROS generation exceeds the capacity of antioxidants,
dampens essential cellular processes and functions of T cells. In innate immune cells, ROS are effec-
tor molecules that are capable of directly killing pathogens as well as act as redox signaling mole-
cules that modulate a wide range of innate immune responses (Schieber and Chandel, 2014;
Mills et al., 2017; Nathan and Cunningham-Bussel, 2013). Accumulating evidence has shown that
ROS production is induced following T cell activation and is required for driving T cell activation and
proliferation (Sena et al., 2013; Kamin´ski et al., 2012). Also, TH17 cells are more sensitive to the
damaging effects of ROS than are Treg cells (Gerriets et al., 2015). A recent study demonstrated a
critical role for GSH biosynthesis in fine-tuning this process by maintaining ROS hemostasis and reg-
ulating Myc-dependent T cell metabolic reprogramming during T cell activation (Mak et al., 2017;
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Klein Geltink et al., 2017). Little information exists, however, on whether and how T cell metabolic
programs modulate T cell GSH biosynthesis and ROS homeostasis.
Here, we report a critical role for de novo GSH synthesis but not recycling of GSSG in modulating
ROS homeostasis and T cell differentiation. Heightened glutamine catabolism during TH17 differenti-
ation provides glutamate to support de novo GSH synthesis and suppresses oxidative stress. Genetic
ablation of de novo synthesis of GSH but not regeneration of GSH from GSSG leads to the augmen-
tation of ROS, dampening TH17 differentiation while enhancing Treg cell differentiation. Moreover,
we found that dimethyl fumarate, an FDA approved drug (BG-12/Tecfidera) for multiple sclerosis,
suppresses TH17 differentiation by augmenting intracellular ROS. Combining pharmacological and
genetic approaches, our studies implicate the GSH-ROS axis as a metabolic checkpoint coordinating
glutamine catabolism and T cell signaling to direct T cell differentiation.
Results
De novo synthesis but not recycling of GSSG is required for producing
GSH and suppressing ROS upon TCR stimulation
T cell activation is associated with enhanced GSH and ROS production (Figure 1—figure supple-
ment 1A and B) (Sena et al., 2013; Kamin´ski et al., 2012; Mak et al., 2017). GSH can be regener-
ated through recycling of glutathione disulfide (GSSG) or synthesized de novo from glutamate,
cysteine and glycine (Figure 1A). GSH regeneration is mediated by glutathione-disulfide reductase
(GSR), whereas de novo synthesis is composed of two steps catalyzed by glutamine-cysteine ligase
(GCL), a heterodimer of a catalytic subunit (GCLC) and a modulatory subunit (GCLM), and glutathi-
one synthase (GS), respectively (Figure 1A). Thus, we examined the expression of the above key
enzymes following T cell activation. Real time quantitative PCR (qPCR) analysis revealed a time-
dependent up-regulation of mRNAs encoding these metabolic enzymes in T cells following activa-
tion (Figure 1—figure supplement 1C).
To determine the extent to which de novo synthesis contributes to GSH production and redox
homeostasis in T cells, we obtained mouse models with genetic deficiencies in GCL. GCLC possesses
all the enzymatic activity, while GCLM functions to optimize the catalytic efficiency of the holoen-
zyme (Chen et al., 2005). Gclm knockout (Gclm KO) mice carry the germ-line deletion of Gclm,
whereas T cell-specific Gclc knockout (T cell-Gclc KO) mice, generated by crossing Gclc-floxed mice
with CD4-Cre mice, carry the Gclc deletion exclusively in T cells (Chen et al., 2007; Yang et al.,
2002). Absent expression of GCLM or GCLC in T cells derived from corresponding animals was con-
firmed by western blot (Figure 1—figure supplement 1D). Next, we examined the intracellular lev-
els of GSH and ROS of T cells that were stimulated with anti-CD3 plus anti-CD28. Deficiency in
GCLC (the catalytic subunit) and, to a lesser extent, deficiency in GCLM (modifier subunit) resulted
in reduced intracellular content of GSH (Figure 1B). Consistent with this, we observed increased
ROS in Gclc- and to a lesser extent in Gclm-deficient T cells as compared to WT T cells. (Figure 1C).
We then sought to determine the extent to which recycling of GSSG contributes to GSH produc-
tion and redox homeostasis in T cells. For this, we obtained mice carrying germ-line deletion of Gsr
(Gsr-/-), the deletion of which was demonstrated by qPCR (Figure 1—figure supplement 1D)
(Rogers et al., 2004; Pretsch, 1999; Yan et al., 2012). However, WT and Gsr-deficient T cells dis-
played comparable GSH and ROS levels (Figure 1B and C). These results suggested that de novo
synthesis of GSH by the metabolic pathway plays an indispensable role in producing GSH and main-
taining redox homeostasis during T cell activation.
GCLC deficiency but not GCLM or GSR deficiency suppresses T cell
activation and proliferation
Gclm KO, T cell-Gclc KO and Gsr KO mice contained comparable numbers and distribution of thy-
mocytes and peripheral CD4+ and CD8+ T cells relative to control mice (Figure 2—figure supple-
ment 1A,B,C and D), indicating a largely undisturbed T cell development and distribution after
double positive stage in the absence of GSH recycling pathway or the de novo synthesis pathway. A
recent study has showed that Gclc deficiency suppressed T cell activation and proliferation, demon-
strating a critical role of GCLC in regulating T cell activation (Mak et al., 2017; Klein Geltink et al.,
2017). This is consistent with the severe GSH depletion and ROS induction in Gclc-deficient active T
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Figure 1. De novo synthesis but not recycling of GSSG is required for producing GSH and fine-tuning ROS upon TCR stimulation. (A) Diagram of GSH
biosynthesis, with metabolic pathways highlighted in red and enzymes highlighted in blue. (B) Naive CD4+T cells from WT and Gclm KO (left), or WT
(CD4-Cre-, Gclcfl/fl) and Gclc KO (CD4-Cre+, Gclcfl/fl, (middle), or WT and Gsr KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24
hr, followed by the measurement of GSH levels. (C) Naive CD4+T cells from WT and Gclm KO (left), or WT (CD4-Cre-, Gclcfl/fl) and Gclc KO (CD4-Cre+,
Figure 1 continued on next page
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cells (Figure 1B and C). Our results further suggested that GSR is dispensable and GCLM only play
a minor role in modulating GSH production and ROS homeostasis in active T cells (Figure 1B and
C). Next, we sought to differentiate the impact of GSH recycling pathway and de novo synthesis
pathway on T cell activation and proliferation. While both Gclc and Gclm deficiency caused a reduc-
tion of GSH and induction of ROS, albeit to different degrees (Figure 1B and C), Gclc but not Gclm
deficiency resulted in an impairment of cell viability, appearance of the activation marker CD25, and
activation-induced cell proliferation (Figure 2A, B, D, E and G). This activation and proliferation
defect is consistent with a recent study showing that GCLC is required for T cell activation
(Mak et al., 2017). Previous studies have shown that GSH depletion caused inactivation of glutathi-
one peroxidase 4 (GPX4), and consequentially led to iron-dependent accumulation of lipid peroxida-
tion and a form of cell necrosis referred as ferroptosis (Stockwell et al., 2017). Our data suggested
that a moderate reduced cell viability in Gclc-deficient T cells is likely due to ferroptosis in the con-
text of GSH depletion (Figure 2G). Our results suggested that a severe depletion of GSH and induc-
tion of ROS caused by Gclc deficiency significantly impaired T cell activation and proliferation,
however, active T cell could tolerate and cope with a moderate depletion of GSH and induction of
ROS caused by Gclm deficiency.
Consistent with its dispensable role in GSH production in active T cells (Figure 1B and C), Gsr
deficiency did not lead to any impairment of T cell viability, activation marker CD25 and proliferation
(Figures 2C, F and G). Notably, none of the above genetic deficiencies compromised the early acti-
vation marker CD69 (Figure 2A–C). Our results suggest that GSH recycling pathway is dispensable
in regulating T cell activation and proliferation. However, the recycling of GSSG to GSH, which is not
a parallel pathway for GSH production, plays a critical role in maintaining redox homeostasis when
the ratio of GSSG:GSH reaches certain threshold. While our data suggest that Gsr mediated recy-
cling of GSSG is not required for T cell activation and proliferation, we do not have evidence show-
ing that GSSG is significantly accumulated during T cell activation and proliferation. Therefore, a
dispensable role of Gsr in maintaining redox homeostasis during T cell activation and proliferation
may represent a context-dependent interpretation.
Ablation of de novo synthesis but not recycling of GSSG reciprocally
alters TH17 and iTreg cell differentiation
Following the initial growth stage of cell activation, proliferating CD4+ T cells can differentiate into
various functional subsets including inflammatory TH17 and Foxp3-expressing regulatory T cells (Treg
cells), which are two closely related subsets with distinct functions. Having found a role for de novo
synthesis of GSH in modulating GSH and ROS homeostasis during T cell activation, we next assessed
the functional requirement for the de novo synthesis pathway of GSH in T cell differentiation. Naive
T cells were differentiated under TH17 or iTreg conditions. As compared to control WT cells, Gclm
KO cells exhibited reduced IL-17+ and increased Foxp3+ cells (Figure 3A and D). Given that a similar
degree of proliferation was observed between WT and Gclm KO CD4+ T cells (Figure 3A and D),
deregulation of cell differentiation in Gclm KO was largely independent of cell expansion. To bypass
the effect of Gclc deficiency on T cell activation and proliferation (Figure 2B and E), we generated a
mouse model carrying a conditional Gclc allele (Gclcflox/flox) and a tamoxifen-induced Cre recombi-
nase (CreERT2) transgene (Ryan et al., 2000; de Luca et al., 2005), which allowed us to delete Gclc
Figure 1 continued
Gclcfl/fl, (middle), or WT and Gsr KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by the measurement of ROS
levels. Data in Figure 1B–C are representative of two independent experiments. Data represent the mean ± S.D.
DOI: https://doi.org/10.7554/eLife.36158.002
The following source data and figure supplements are available for figure 1:
Source data 1. Source data for B and C.
DOI: https://doi.org/10.7554/eLife.36158.005
Figure supplement 1. TCR stimulation drives GSH and ROS production in T cells.
DOI: https://doi.org/10.7554/eLife.36158.003
Figure supplement 1—source data 1. Source data for A, B, C and D.
DOI: https://doi.org/10.7554/eLife.36158.004
Lian et al. eLife 2018;7:e36158. DOI: https://doi.org/10.7554/eLife.36158 5 of 28
Research article Immunology and Inflammation
AED
CFSE
E
v
e
n
ts
(%
 o
f 
m
a
x
)
F
B
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD25
C
WT
Gclm-KO
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD69
WT
Gclm-KO
WT
Gclc-KO
WT
Gclc-KO
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD25
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD69
WT
Gsr-KO
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD25
WT
Gsr-KO
E
v
e
n
ts
(%
 o
f 
m
a
x
)
CD69
WT
Gclm-KO
CFSE
E
v
e
n
ts
(%
 o
f 
m
a
x
)
Cre- (WT)
Cre+ (Gclc-
KO)
CFSE 
E
v
e
n
ts
(%
 o
f 
m
a
x
)
WT
Gsr-KO
G
WT
Gclm
KO
WT
Gclc
KO
WT
Gsr
KO
FSC
7
A
A
D
FSC
7
A
A
D
FSC
7
A
A
D
84.2 80.8 81.1
83.7 66.7 76.1
Figure 2. Severe depletion of GSH by blocking de novo synthesis suppresses T cell activation and proliferation. (A–C) Naive CD4 +T cells from WT and
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(72 hr) with indicated genotypes was determined by CFSE dilution. (G) Naive CD4 +T cells isolated from mice with indicated genotypes were activated
Figure 2 continued on next page
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flox alleles in an acute manner. For this, we polarized T cells in the absence (WT) or in the presence
(KO) of 4-Hydroxytamoxifen (4OHT) (Figure 3—figure supplement 1A). As compared with WT cells,
acute deletion of Gclc bypassed its required for cell proliferation, as revealed by a comparable CFSE
dilution (Figure 3B and E), but nevertheless resulted in a reduction in the generation of IL-17+ T cells
and an induction in the generation of Foxp3+ cells. Using this genetic model, we have therefore dif-
ferentiated the role of GCLC in early T cell activation from its role in driving TH17 cell differentiation.
In contrast to the effects of ablation of Gclm and Gclc, Gsr KO and WT CD4+ T cells displayed a sim-
ilar degree of TH17 and iTreg differentiation, indicating a dispensable role for recycling GSSG in regu-
lating T cell differentiation (Figure 3C and F). Next, we tested whether inhibiting ROS generation in
T cells that have defects on the de novo synthesis of GSH would restore TH17 differentiation. The
addition of N-acetyl-L-cysteine (NAC), a reagent often used to scavenge ROS, restored TH17 cell dif-
ferentiation in Gclc-/- T cells (Figure 3—figure supplement 1B). While NAC is frequently considered
a source of cysteine for synthesis of GSH, while other studies have shown that NAC displayed reduc-
ing properties through its thiol-disulfide exchange activity and could directly scavenge free radicals
(Ates et al., 2008; Agnihotri and Mishra, 2009; Zafarullah et al., 2003; Cotgreave, 1997). Consis-
tent with these, our result suggests that NAC scavenges ROS independently of GSH synthesis (Fig-
ure 3—figure supplement 1C and D) and therefore restores TH17 cell differentiation in Gclc
-/- T
cells. To further evaluate the role of the GSH de novo synthesis pathway in TH17-driven EAE in vivo,
we immunized mice with the myelin oligodendrocyte glycoprotein (MOG)35-55 antigen. Genetic abla-
tion of GCLM or GCLC conferred a protection against disease progression (Figure 3G and H). Fur-
thermore, histological assessment revealed a similar degree of ablation of T cell infiltration in Gclm
KO and T cell-Gclc KO animals compared to WT animals (Figure 3—figure supplement 1E). How-
ever, a different degree of ablation of macrophage infiltration in Gclm KO and T cell-Gclc KO ani-
mals compared to WT animals was observed and likely reflected a different level of inflammation in
these experimental animals (Figure 3—figure supplement 1E). In contrast to T cell-Gclc KO animals,
GCLM is also deleted in macrophages in Gclm KO animal (a germline KO model). Therefore, we
could not exclude the possibility that Gclm deficiency in macrophages might affect macrophage infil-
tration in our result. Collectively, our studies suggested that de novo synthesis of GSH is required
for TH17 development in vitro and TH17-driven CNS inflammation in vivo.
TH17 and iTreg cells display different degrees of oxidative stress
Accumulating evidence has shown that each subset of T cells engages unique metabolic pathways to
fulfill its metabolic demands (Shi et al., 2011; Michalek et al., 2011; Gerriets et al., 2015). We envi-
sioned that the differential engagement of metabolic pathways would differentially impact GSH bio-
synthesis and cellular oxidative stress in TH17 and iTreg cells. For this, we activated naive CD4
+ T
cells under TH17 or iTreg polarizing conditions in vitro, and examined the intracellular levels of GSH
and ROS at day 3 and day 5. TH17 cells displayed a higher level of intracellular GSH than iTreg cells.
In contrast, the level of ROS was lower in TH17 cells compared to iTreg cells (Figure 4A and B). In
addition, TH17 cells displayed a higher level of intracellular GSH and GSSG than iTreg cells, as
revealed by mass spectrometry (Figure 4C). A key cellular mechanism in defending against oxidative
stress is through activation of nuclear factor erythroid 2-related factor 2 (NRF2), which controls the
expression of genes involved in producing, regenerating, and utilizing GSH. NRF2 also controls
other antioxidant pathways that regulate thioredoxin (TXN), NADPH generation and iron sequestra-
tion (Jaramillo and Zhang, 2013; Sporn and Liby, 2012; Ma, 2013; Motohashi and Yamamoto,
Figure 2 continued
by plate-bound anti-CD3 and anti-CD28 for 24 hr. Cell viability was determined by FACS. Figure 2A–G are representative of three independent
experiments.
DOI: https://doi.org/10.7554/eLife.36158.006
The following source data and figure supplements are available for figure 2:
Figure supplement 1. Severe depletion of GSH by blocking de novo synthesis suppresses T cell activation and proliferation.
DOI: https://doi.org/10.7554/eLife.36158.007
Figure supplement 1—source data 1. Source data for A, B, C and D.
DOI: https://doi.org/10.7554/eLife.36158.008
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Figure 3 continued on next page
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2004). Consistent with increased levels of GSH and decreased levels of ROS in TH17 cells, qPCR
analysis revealed a time-dependent up-regulation of mRNAs encoding NRF2 and its target genes,
including glucose-6-phosphate dehydrogenase (G6PD), TXN, thioredoxin reductase 1 (Txnrd1),
CD44, heme oxygenase-1 (Hmox1), NAD(P)H quinone dehydrogenase 1 (Nqo1) and glutathione syn-
thetase (Gss) (Figure 4—figure supplement 1A). These results suggested that TH17 cells preferen-
tially maintain a low degree of oxidative stress by a tight regulation of GSH synthesis and ROS
homeostasis.
De novo synthesis but not recycling of GSSG is required for producing
GSH and suppressing ROS during TH17 cell differentiation
The observation that TH17 cells displayed increased GSH content and decreased levels of ROS than
iTreg cells supported the role for GSH in directing TH17 cell differentiation (Figure 4A and B). Next,
we sought to determine how two GSH synthetic pathways are engaged and impact on GSH and
ROS homeostasis during TH17 cell differentiation. For this, we purified naive T cells and differenti-
ated them under TH17-polarizing conditions. Deficiency in Gclc and, to a lesser extent, deficiency in
Gclm resulted in reduced intracellular content of GSH (Figure 4D). Consistent with this, we observed
increased ROS in Gclc- and Gclm-deficient T cells as compared to WT T cells (Figure 4—figure sup-
plement 1B and C). By contrast, WT and Gsr-deficient T cells displayed comparable GSH sand ROS
levels (Figure 4—figure supplement 1D). These results indicated that the preferential requirement
for de novo synthesis of GSH during the initial T cell activation stage is extended to the later T cell
differentiation stage. However, the recycling pathway is dispensable in producing GSH and maintain-
ing redox homeostasis during TH17 differentiation.
Pharmacological augmentation of ROS reciprocally modulates TH17 and
iTreg cell differentiation
We next asked whether shifting the redox balance towards an oxidative state would perturb T cell
differentiation and represent a novel therapeutic strategy for T cell-driven autoimmunity. For this,
we activated naive CD4+ T cells under TH17 or iTreg polarizing conditions in the presence or absence
of H2O2. Addition of 1 mM H2O2 did not impact cell proliferation but reciprocally reduced TH17 and
enhanced iTreg cell differentiation (Figure 5A and B), indicating that its effect on differentiation was
largely independent of expansion.
The observation of H2O2-dependent suppression of TH17 differentiation prompted us to explore
pharmacologic approaches that could augment ROS production in T cells. Dimethyl fumarate (DMF),
the key active ingredient of BG-12/TECFIDERA and FUMADERM, has been approved in many coun-
tries for treating autoimmune diseases including multiple sclerosis (MS) and psoriasis, both of which
are associated with pathogenic TH17 cells (Study group et al., 2014; Mrowietz et al., 2007;
DEFINE Study Investigators et al., 2012; CONFIRM Study Investigators et al., 2012). However,
the cellular and molecular mechanisms underlying the therapeutic efficacy of DMF have not been
fully elucidated (Kees, 2013). Previous studies have implicated DMF in regulating the cellular activi-
ties of dendritic cells (DCs), endothelial cells, and neurons through various mechanisms
(Blewett et al., 2016; Schulze-Topphoff et al., 2016; Wang et al., 2015; Chen et al., 2014;
Peng et al., 2012; Linker and Gold, 2013; Duffy et al., 1998; Gill and Kolson, 2013). The
Figure 3 continued
with indicated genotypes were immunized with MOG to induce EAE and pathological progressions were scored daily. Data in Figure 4A–H are
representative of two-three independent experiments.
DOI: https://doi.org/10.7554/eLife.36158.009
The following source data and figure supplements are available for figure 3:
Source data 1. Source data for G and H.
DOI: https://doi.org/10.7554/eLife.36158.012
Figure supplement 1. Ablation of de novo synthesis but not recycling of GSSG reciprocally alters TH17 and iTreg cell differentiation.
DOI: https://doi.org/10.7554/eLife.36158.010
Figure supplement 1—source data 1. Source data for C and D.
DOI: https://doi.org/10.7554/eLife.36158.011
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Figure 4. TH17 cells preferentially maintain higher level of GSH than iTreg cells. (A–B) Naive CD4
+ T cells from C57BL/6 mice were differentiated under
iTreg or TH17–inducing conditions and cells were collected at indicated times, followed by measuring intracellular GSH (A) and ROS (B) by FACS. (C)
Naive CD4+ T cells from C57BL/6 mice were differentiated under TH17 or iTreg–inducing conditions for 5 days. The intracellular levels of GSH and GSSG
were determined by mass spectrometry. (D) Naive CD4+T cells from WT and Gclm KO (top) or WT (CD4-Cre-, Gclcfl/fl) and Gclc KO (CD4-Cre+, Gclcfl/fl,
Figure 4 continued on next page
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electrophilic nature of DMF allows it to bind and deplete intracellular GSH (Zheng et al., 2015;
Sullivan et al., 2013). We therefore hypothesized that DMF may induce oxidative stress and affect T
cell differentiation. To test this, we activated naive CD4+ T cells under TH17 polarizing conditions in
the presence of a range of DMF doses based on previous reports that were designed to investigate
the effect of DMF on other cell types (Peng et al., 2012; Linker and Gold, 2013; Duffy et al.,
1998). DMF treatment displayed a dosage-dependent suppression of TH17 cell differentiation
(Figure 5C). Although the addition of 75 mM DMF inhibited T cell proliferation, at the lower dose of
DMF used in this study (20–50 mM), we observed minimal inhibitory effects of DMF on cell prolifera-
tion (Figure 5—figure supplement 1A), indicating that DMF-mediated suppression on TH17 differ-
entiation was largely independent of cell proliferation. Moreover, DMF treatments induced ROS
production in TH17 cells (Figure 5D). Consistent with the idea that DMF suppresses TH17 cell differ-
entiation through the induction of oxidative stress, the addition of N-acetyl-L-cysteine (NAC)
restored TH17 cell differentiation in the presence of DMF (Figure 5E). Since H2O2 treatment recipro-
cally reduced TH17 and enhanced iTreg cell differentiation (Figure 5A and B), we next assessed the
effect of DMF on iTreg cell differentiation. However, the doses of DMF (5 and 20 mM) that could sup-
press TH17 differentiation failed to affect iTreg cell differentiation in vitro (Figure 5—figure supple-
ment 1B). As such, our data suggested that DMF may partially exert its immunomodulatory action
through the augmentation of oxidative stress and suppressing TH17 differentiation. Along with the
possibility that DMF-derived fumarate interferes with TCA cycle intermediate metabolite pool, other
mechanisms may also contribute to its immunomodulatory functions (Blewett et al., 2016; Schulze-
Topphoff et al., 2016; Wang et al., 2015; Chen et al., 2014; Peng et al., 2012; Linker and Gold,
2013; Duffy et al., 1998; Gill and Kolson, 2013).
Glutamate that fuels GSH de novo synthesis is partially derived from
glutamine during TH17 cell differentiation
Upon activation, a metabolic reprogramming is required for directing nutrients to meet the bioener-
getic, biosynthetic, and redox demands, which prepares T cells for immune defense and regulation.
We and others have shown that T cell metabolism changes from relying on FAO and some mito-
chondria-dependent glucose oxidation to engaging robust aerobic glycolysis and glutaminolysis
(Wang et al., 2011; Frauwirth et al., 2002; Jacobs et al., 2008; Gerriets and Rathmell, 2012;
Pearce et al., 2009). Glutamine catabolism not only fuels mitochondrial ATP production through the
TCA cycle but also provides metabolic precursors for multiple biosynthetic pathways, including syn-
thesis of glutathione (GSH), an essential cellular antioxidant system to maintain redox homeostasis
during T cell activation (Altman et al., 2016; Hensley et al., 2013; Gorrini et al., 2013; Mak et al.,
2017). The de novo synthesis of GSH requires glycine, cysteine and glutamate as metabolic precur-
sors. We envisioned that glutamine-derived glutamate partially fulfils the requirement of de novo
synthesis of GSH in TH17 cells (Figure 6A). To test this hypothesis, we followed U-
13C,15N labeled
glutamine incorporation into glutamate and GSH. The 13C5 isotopologues (generated via a direct
Glutamine to Glutmate conversion) represented a significant fraction of the total glutamate and
GSH pool in both TH17 and iTreg cells, however, the absolute quantity of
13C5-glutamate and
13C5-
GSH is higher in TH17 cells than in iTreg cells (Figure 6B). These results suggested that TH17 cells
could uptake more glutamine and/or produce more glutamate for GSH synthesis than iTreg cells. In
Figure 4 continued
(bottom) were differentiated under TH17-inducing conditions for 5 days, followed by the measurement of GSH levels. Data in Figure 4A–D are
representative of three independent experiments. Data represent the mean ± S.D.
DOI: https://doi.org/10.7554/eLife.36158.013
The following source data and figure supplements are available for figure 4:
Source data 1. Source data for A, B, C and D.
DOI: https://doi.org/10.7554/eLife.36158.016
Figure supplement 1. De novo synthesis but not recycling of GSSG is required for providing GSH and suppressing ROS during TH17 cell
differentiation.
DOI: https://doi.org/10.7554/eLife.36158.014
Figure supplement 1—source data 1. Source data for A, B and C.
DOI: https://doi.org/10.7554/eLife.36158.015
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Figure 5. DMF suppresses TH17 differentiation by augmenting ROS generation. (A) Naive CD4
+ T cells from C57BL/6 mice were differentiated under
TH17 or iTreg-inducing conditions with or without H2O2 (1 mM) for 5 days, followed by intracellular staining of IL-17 and Foxp3. (B) Cell proliferation of
active CD4+ T cells (72 hr) with or without H2O2 (1 mM) was determined as CFSE dilution. (C–D) Naive CD4
+ T cells from C57BL/6 mice were
differentiated under TH17-inducing conditions with indicated dose of DMF for 5 days, followed by intracellular staining of IL-17 (C) and ROS (D). (E)
Figure 5 continued on next page
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accord with this data, glutamine starvation reduced GSH content in a time-dependent manner in
TH17 cells (Figure 6—figure supplement 1A). In addition to support GSH biosynthesis, glutamine-
derived glutamate can also feed into the TCA cycle. We therefore utilized radiochemical-based
approaches to assess activities of glutamine oxidation through the TCA cycle in TH17 and iTreg cells.
TH17 cells displayed higher glutamine oxidation activity, indicated by
14CO2 release from [U-
14C]-
glutamine, than did iTreg cells (Figure 6C). However, mitochondria-dependent pyruvate oxidation
through the TCA cycle, indicated by 14CO2 release from [2-
14C]-pyruvate, was comparable between
the two functional subsets (Figure 6C). These data further suggested that the overall uptake and
consumption of glutamine, including oxidation of glutamate through the TCA cycle and utilization of
glutamate for GSH biosynthesis is enhanced in TH17 comparing to iTreg cells. Also, qPCR analyses
revealed marked upregulation of genes encoding various molecules involved in glutamine catabo-
lism and GSH metabolism in TH17 compared to iTreg cells (Figure 6—figure supplement 1B and C).
Consistent with this, deprivation of glutamine significantly suppressed TH17 but moderately
enhanced iTreg cell differentiation (Figure 6D), while both TH17 and iTreg differentiation required glu-
cose (Figure 6E). Next, we asked if pharmacological inhibition of the rate-limiting glutaminolyic
enzyme glutaminase (Gls) could impact T cell differentiation. Two Gls1 specific inhibitors, bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) and CB-839 (Wang et al., 2010;
Le et al., 2012), slightly enhanced IL-17 expression (Figure 6—figure supplement 1D). However, 6-
diazo-5-oxo-l-norleucine (DON), an analog of glutamine with broad inhibitory effects glutamine uti-
lizing enzymes (Pinkus, 1977; Shapiro et al., 1979), skewed away T cells from TH17 toward iTreg dif-
ferentiation (Figure 6—figure supplement 1D). In addition, DON but not BPTES and CB-839
significantly enhanced ROS production under TH17-polarizing condition (Figure 6—figure supple-
ment 1E). These results suggested that other glutamine utilizing enzymes including glutamine-
dependent amidotransferase and Gls2, the latter of which has been shown to be induced upon T
cell activation (Wang et al., 2011; Zalkin and Smith, 1998; Massie`re and Badet-Denisot, 1998).
Glutamine catabolism is not only coupled to the de novo synthesis of GSH, but also generates the
anaplerotic substrate, a-ketoglutarate (a-KG), and substrates for nucleotide biosynthesis
(Altman et al., 2016). A previous study demonstrated that glutamine deprivation enhances iTreg dif-
ferentiation and addition of a-KG could compromise such effect (Klysz et al., 2015). In line with this
report, addition of either hypoxanthine and thymidine (HT) or a-KG was able to partially rescue TH17
differentiation in glutamine-free condition without impacting ROS level (Figure 6F and G). While
NAC treatment is sufficient to suppress ROS production, it was incapable of rescuing TH17 differenti-
ation (Figure 6—figure supplement 1G). However, the combination of HT and NAC led to more dif-
ferentiated TH17 cells and lower level of ROS comparing to HT treatment alone in the absence of
glutamine (Figure 6—figure supplement 1F). Taken together, our studies suggest that glutamine
catabolism directs the lineage choices between TH17 and iTreg cells through supporting T cell prolif-
eration by providing biosynthetic precursors. In addition, glutamine-derived glutamate provides a
key substrate for the de novo synthesis of GSH, modulates ROS signaling, and may also impact T
cell differentiation (Figure 6—figure supplement 2).
Discussion
A robust T cell-mediated adaptive immune response results from the clonal expansion of antigen-
specific T cells and subsequent differentiation into diverse functional subsets to fine-tune responses
against challenge. Both the cellular proliferation during expansion and the cytokine production
Figure 5 continued
Naive CD4+ T cells from C57BL/6 mice were differentiated under TH17-inducing conditions with indicated treatment for 5 days, followed by intracellular
staining of IL-17. Data in Figure 5 are representative of two-three independent experiments. Data represent the mean ±S.D.
DOI: https://doi.org/10.7554/eLife.36158.017
The following source data and figure supplement are available for figure 5:
Source data 1. Source data for D.
DOI: https://doi.org/10.7554/eLife.36158.019
Figure supplement 1. DMF suppresses TH17 differentiation through augmenting ROS generation.
DOI: https://doi.org/10.7554/eLife.36158.018
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Figure 6. Glutamate that fuels GSH de novo synthesis is partially derived from glutamine in T cells. (A) Diagram of metabolic steps linked to the GSH
production, with metabolic pathways highlighted in red. (B) Naive CD4+ T cells from C57BL/6 mice were differentiated under TH17 and iTreg–inducing
conditions for 5 days, followed by culturing in media containing 13C5
15N2-glutamine. The intracellular levels of Glutamate and GSH including
13C-,
13C,15N-, and 12C-unlabeled forms were determined by IC-UHRFTMS. (C) Naive CD4+ T cells from C57BL/6 mice were differentiated under TH17 or iTreg
Figure 6 continued on next page
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associated with differentiation exert high bioenergetic and biosynthetic demand on T cells. Accord-
ingly, rapidly evolving pathogens often impose selective pressures on the regulation of central meta-
bolic pathways that fuel cell proliferation and differentiation, allowing T cells to maintain
homeostasis while remaining ready to mount rapid responses under diverse metabolic and immune
conditions. The inability to accommodate the metabolic and bioenergetic demands of T cell prolifer-
ation and differentiation can impair the proper development and function of T cells. Beyond this, the
availability of specific metabolites, and the pathways that process them, interconnect with signaling
events in the cell to orchestrate metabolic checkpoints which influence T cell activation, differentia-
tion, and immune function (Wang and Green, 2012; Bensinger and Tontonoz, 2008; Gerriets and
Rathmell, 2012; Pearce et al., 2013; Chi, 2012; Powell and Delgoffe, 2010; Michalek and Rath-
mell, 2010; Ho et al., 2015). Here, we found that glucose plays an indispensable role in driving
TH17 and iTreg cell differentiation, while glutamine is only required for TH17 cell differentiation. Glu-
tamine catabolism is coupled with de novo GSH synthesis and is preferentially elevated during TH17
but not iTreg cell differentiation, suggesting that different T cell lineages ‘wire’ metabolism differ-
ently to support their development and function. Previous studies have suggested that engagement
of the transcription factor hypoxia-inducible factor 1a (HIF1a) coordinates glycolysis and T cell sig-
naling cascades to regulate the differentiation of TH17 and iTreg cells (Shi et al., 2011; Dang et al.,
2011). While the high rate of glutamine catabolism ensures the capacity to supply glutamate, glycol-
ysis provides ATP and biosynthetic precursors for glycine, fulfilling the needs of de novo synthesis of
GSH during T cell differentiation. Our results using genetic modulation of metabolic enzymes sug-
gest that de novo synthesis of GSH but not recycling from GSSG is required for fine-tuning ROS and
directing the differentiation of TH17 and Treg cells. We further found that dimethyl fumarate, a FDA
approved drug (BG-12/Tecfidera) for multiple sclerosis, suppresses TH17 differentiation by augment-
ing intracellular ROS. While previous studies clearly demonstrate that activation-induced metabolic
reprogramming is required for driving T cell growth and proliferation, our studies shed light on the
complex utilization of the glutamine catabolic pathway and implicate ROS as essential metabolic sig-
nals that dictate T cell lineage engagement.
Prokaryotic and eukaryotic cells have evolved to maintain reducing intracellular conditions by
generating reducing equivalents, NADPH and GSH, enabling cells to fine-tune the ROS levels that
are required for fulfilling vital cellular functions. Accordingly, oxidative stress occurs if the balance
between ROS production and antioxidant capacity is disturbed, thereby leading to the accumulation
of oxidized biomolecules. T cell receptor (TCR) engagement induces a rapid generation of mitochon-
drial ROS from OXPHOS and cytoplasmic ROS from NADPH oxidases (NOXs), a family of plasma
membrane associated oxidases (Sena et al., 2013; Kamin´ski et al., 2012; Jackson et al., 2004). T
cells with reduced production of mitochondrial ROS display impaired production of interleukin 2 (IL-
2) and antigen-specific proliferation, indicating an essential signaling role for mitochondrial ROS in
driving optimal TCR signaling (Sena et al., 2013; Kamin´ski et al., 2012). Beyond that, NOX-
Figure 6 continued
cell–inducing conditions for 5 days, were used for measuring the generation of 14CO2 from [U-14C]-glutamine (glutaminolysis), from [2-14C]-pyrvuate
(TCA). (D–E) Naive CD4+ T cells from C57BL/6 mice were differentiated in completed, glutamine-free (Q free) or glucose-free (G free) medium under
TH17 or iTreg cell-inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3. (F) Naive CD4
+ T cells from C57BL/6 mice were
activated in complete medium for 24 hr and cells were washed with PBS and switch to conditional medium in presence or absence of glutamine, 3 mM
aKG or 100 mM hypoxanthine and 16 mM thymidine (HT) for 5 days followed by intracellular staining of IL-17 and (G) and ROS. Data represent the
mean ±S.D.
DOI: https://doi.org/10.7554/eLife.36158.020
The following source data and figure supplements are available for figure 6:
Source data 1. Source data for B, C and G.
DOI: https://doi.org/10.7554/eLife.36158.024
Figure supplement 1. Glutamine catabolism is required for driving TH17 and iTreg cell differentiation.
DOI: https://doi.org/10.7554/eLife.36158.021
Figure supplement 1—source data 1. Source data for A, B, C, E and G.
DOI: https://doi.org/10.7554/eLife.36158.022
Figure supplement 2. Glutamine catabolism coordinates with GSH metabolism in modulating ROS homeostasis and T cell differentiation.
DOI: https://doi.org/10.7554/eLife.36158.023
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dependent ROS also plays a role in modulating TCR signaling and T cell differentiation. T cells with
low levels of ROS due to NOX deficiency are skewed toward a TH17 phenotype (Jackson et al.,
2004; Purushothaman and Sarin, 2009; Padgett and Tse, 2016; Tse et al., 2010). Our studies sug-
gest that de novo synthesis of GSH is essential for fine-tuning ROS levels in T cells and also indicate
the differential requirements for the level of ROS in driving T cell lineage engagement toward TH17
or iTreg cells. Understanding the metabolic process of GSH synthesis and ROS generation during T
cell differentiation may also impact the development of safer and more effective therapies for auto-
immune and inflammation diseases. Dimethyl fumarate (DMF) is a cellular permeable analog of fuma-
rate and the key active ingredient of BG-12/TECFIDERA and FUMADERM, a first-line oral treatment
for relapsing multiple sclerosis (CONFIRM Study Investigators et al., 2012; ALLEGRO Study
Group et al., 2012). However, the cellular and molecular mechanisms of DMF therapy remain largely
elusive. DMF has been suggested to impact a plethora of cellular and molecular targets, including
Nrf2 and GPCRs in T cells, dendritic cells (DCs), endothelial cells, and neurons (Blewett et al., 2016;
Schulze-Topphoff et al., 2016; Wang et al., 2015; Chen et al., 2014; Peng et al., 2012;
Linker and Gold, 2013; Duffy et al., 1998; Gill and Kolson, 2013). Consistent with the studies
showing that DMF can neutralize GSH in vitro (Zheng et al., 2015; Sullivan et al., 2013), our data
indicate that the ability of DMF to augment ROS and suppress TH17 cell differentiation contributes
to its therapeutic effect.
We found that DMF treatment induced a compensatory NRF2-mediated anti-oxidative response
and NRF2 deficiency exacerbated the ROS-producing effects of DMF in TH17 cells. Also, NRF2 and
its target genes were highly upregulated in TH17 cells, suggesting that TH17 cells preferentially main-
tain a low degree of oxidative stress partially by engaging the NRF2 signaling pathway. In addition
to GSH production and consumption, NRF2 controls thioredoxin (TXN) production and consumption
through transcriptional regulation of its target genes including thioredoxin reductase 1 (TXNRD1).
Both GSH and TXN are important anti-oxidation systems and appear functionally redundant in most
organisms (Couto et al., 2016; Mustacich and Powis, 2000; Lei et al., 2016; Lu and Holmgren,
2014). However, recent studies implicate the presence of a dynamic cross-talk between these two
systems. Glutaredoxin (GRX)-GSH can reduce oxidized TXN in the absence of thioredoxin reductase.
Conversely, TXN-TXNRD can also function as an alternative system to reduce GSSG to GSH
(Du et al., 2012; Tan et al., 2010; Johansson et al., 2004; Hanschmann et al., 2010). Collectively,
these data indicate that the TXN and GSH systems can backup for each other under certain condi-
tions. Consistent with the overlapping function of the GSH and TXN system, the inhibition of TXNRD
rendered cancer cells susceptible to the depletion of GSH (Mandal et al., 2010; Lu et al., 2007;
Wang et al., 2012). Although our data suggest that the de novo synthesis of GSH is sufficient to
maintain ROS homeostasis in the absence of Gsr dependent GSSG-GSH recycling, it is still conceiv-
able that thioredoxin reductase may partially compensate for the loss of Gsr by backing up the recy-
cle of GSSG to GSH in T cells. It has been shown that TXN can be secreted by CD4+ T cells and may
modulate the expression of T cell surface receptor and proliferation (Rosen et al., 1995;
Wakasugi et al., 1990; Matthias et al., 2002; Tagaya et al., 1990). As such, we envision that the
combination of DMF and pharmacological approaches that target TXN system may represent a
more effective strategy than DMF alone for treating T cell-mediated inflammation and autoimmune
disease.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Strain, strain
background
(Mus musculus)
C57BL/6 (B6) mice Taconic
Strain, strain
background
(Mus musculus)
C3H/HeN Envigo
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Genetic
reagent
(Mus musculus)
CD4-Cre
Gclcflox/flox
PMID:23226398
Genetic
reagent
(Mus musculus)
Gclm-KO PMID:12384496
Genetic
reagent
(Mus musculus)
ROSA26CreERT2 RRID:
IMSR_JAX:008463
The Jackson
Laboratory
Genetic
reagent
(Mus musculus)
GSR-KO PMID: 10218442
Antibody Mouse anti-
CD3 mAb
Cat. #:BE0001-1,
RRID:AB_1107634
BioXcell
Antibody Mouse anti-
CD28 mAb
Cat. #BE0015-1
RRID:AB_1107624
BioXcell
Antibody Mouse anti
-IL2 mAb
Cat.#BE0043
RRID::AB_1107702
BioXcell
Antibody Mouse anti-
IL4 mAb
Cat. #BE0045
RRID:AB_1107707
BioXcell
Antibody Mouse anti-
IFNg mAb
Cat. #BE0055
RRID:AB_1107694
BioXcell
Antibody Anti mouse
CD4-FITC
Cat. #11–0042
RRID:AB_464897
eBioscience (1:200)
Antibody Anti mouse
CD4-APC
Cat. #17-0041-81
RRID:AB_469319
eBioscience (1:200)
Antibody Anti mouse
CD8-APC-Cy7
Cat. #100714
RRID:AB_312753
Biolegend (1:200)
Antibody Anti mouse
Foxp3-APC
Cat. #
RRID:AB_469456
eBioscience (1:200)
Antibody Anti mouse
IL-17A-PECy7
Cat. #25-7177-82
RRID:AB_10732356
eBioscience (1:200)
Antibody Anti GCLC antibody
(rabbit monoclonal)
Cat. #ab190685
RRID:AB_10975474
Abcam WB (1:1000)
Antibody Anti GCLM antibody
(rabbit monoclonal)
Cat. #ab124827
RRID:AB_10975474
Abcam WB (1:1000)
Antibody anti-mouse
CD25 -PE
Cat. #101904
RRID:AB_312847
Biolegend (1:200)
Antibody anti-mouse
CD69-PECy7
Cat. #552879
RRID:AB_394508
BD Bioscience (1:200)
Antibody Anti mouse
monoclonal CD3
Cat. #sc-101442
RRID:AB_1120355
Santa Cruz IHC (1:50)
Antibody Anti mouse
monoclonal
galectin-3
Cat. #sc-32790,
RRID:AB_627657
Santa Cruz IHC (1:50)
Peptide,
recombinant protein
MOG35-55 peptide synthesized
and HPLC-purified
St. Jude
Hartwell Center
for Biotechnology
Peptide,
recombinant protein
Recombinant
mouse IL-6
216–16 Peprotech
Peptide,
recombinant protein
Recombinant
human TGFb
100–21 c Peprotech
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Peptide,
recombinant protein
Recombinant
human or mouse IL-2
200–02 Peprotech
Commercial
assay or kit
Foxp3/Transcription
Factor Staining
Buffer Set
00-5523-00 e-Bioscience
Commercial
assay or kit
Naive CD4 + T cell
isolation kit,mouse
5160725186 Miltenyi Biotec
Commercial
assay or kit
CD45R(B220)
microbeads, mouse
5150309030 Miltenyi Biotec
Commercial
assay or kit
ABC kit PK-7200 Vector
laboratories
Commercial
assay or kit
MojoSort Mouse
naive CD4 T Cell
Isolation Kit
480031 Biolegend
Chemical
compound, drug
Diethly Fumerate Sigma Aldrich D95654
Chemical
compound, drug
N-Acetyl-L-cysteine Sigma-Aldrich A7250
Chemical
compound, drug
Tamofixen Sigma-Aldrich T5648
Chemical
compound, drug
4-hydroxytamoxifen Sigma H7904
Chemical
compound, drug
Dimethy a-keto
glutarate/aKG
Sigma-Aldrich 34963–1
Chemical
compound, drug
Hypoxathine Sigma-Aldrich H9377
Chemical
compound, drug
Thymidine Sigma T9250
Chemical
compound, drug
H2O2 Sigma-Aldrich 7722-84-1
Chemical
compound, drug
carboxyfluorescein
diacetate
succinimidyl
ester(CFSE)
Invitrogen C1157
Chemical
compound, drug
DM-H2DCFDA Invitrogen C6827
Chemical
compound, drug
DAB Vector
Laboratories
SK-4100
Chemical
compound, drug
Monobromobimane Invitrogen M1378
Chemical
compound, drug
7-amino-
actinomycin D(7AAD)
Biolegend 420404
Chemical
compound, drug
Pertussis toxin 181 List Biological
Laboratories
Chemical
compound, drug
Mycobacterium
tuberculosum
231141 Difco
Chemical
compound, drug
Incomplete
Freund’s Adjuvant
263910 Difco
Chemical
compound, drug
[U-14C]-glutamine MC 1124 Moravek
Chemical
compound, drug
[2–14C]-pyruvate ARC 0222 American
Radiolabeled
Chemicals
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Chemical
compound, drug
Cell Stimulation
Cocktail (plus
protein transport
inhibitors) (500X)
00-4975-93 eBioscience
Chemical
compound, drug
Iscove’s Modified
Dulbecco’s Media
- Glucose free
conditional medium
ME17058P1 Thermo
Fisher Scientific
Chemical
compound, drug
Iscove’s Modified
Dulbecco’s Media
- without L-glutamine
12–726 f Lonza
Chemical
compound, drug
RPMI 1640
Medium, No Glucose
11-879-020 Gibco
Chemical
compound, drug
Hyclone RPMI
1640 Medium,
no glutamine
sh30096.10 Thermo
Fisher Scientific
Chemical
compound, drug
U-13C6-glutamine CNLM-1275–0.1 Cambridge
Isotope Lab
Chemical
compound, drug
6-Diazo-5-oxo-L
-norleucine
D2141-5MG Sigma-aldrich
Chemical
compound, drug
Bis-2-
(5-phenylacetamido
-1,3,4-thiadiazol-2-yl)
ethyl sulfide (BPTES)
SML0601 Sigma-aldrich
Chemical
compound, drug
CB-839 22038 Cayman
Software,
algorithm
Graphpad Prism RRID:SCR_002798
Software,
algorithm
FlowJo RRID:SCR_008520
Mice
Gsr-KO mice are on C3H/HeN background and ROSA26CreERT2, CD4-Cre, Gclm-KO, and Gclcflox/
flox are on the C57BL/6 background and were previously described (Wang et al., 2011; Chen et al.,
2007; Yang et al., 2002; Rogers et al., 2004; Pretsch, 1999; Yan et al., 2012) C57BL/6 mice were
purchased from Envigo (formly Harlan). Mice at 8–12 weeks of age were used in the experiment and
were kept in specific pathogen-free conditions within the Animal Resource Center at the Research
Institute at Nationwide Children’s Hospital or St. Jude Children’s, Research Hospital. Animal proto-
cols were approved by the Institutional Animal Care and Use Committee of the Research Institute at
Nationwide Children’s Hospital or St. Jude Children’s Research Hospital.
Flow cytometry
For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) BSA and the appro-
priate antibodies from eBioscience. Foxp3 staining was performed according to the manufacturer’s
instructions (eBioscience). For IL-17A intracellular cytokine staining, T cells were stimulated for 4-5 h
with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of monensin before
being stained according to the manufacturer’s instructions (BD Bioscience). For ROS measurement,
cells were cultured in fresh serum-free IMDM media containing 5 mM H2DCF-DA (BD Bioscience) for
30 min at 37˚C before being washed and resuspended with serum-free IMDM media. The fluores-
cence intensity was measured by flow cytometry. For GSH measurement, cells were cultured in PBS
(1%FBS) containing 50mM monobromobimane (Biochemika) for 10 min at 37˚C before being washed
and resuspended with PBS. The fluorescence at 450/50 nm (blue spectra) was measured by flow
cytometry (Cossarizza et al., 2009). Flow cytometry data were acquired on Novocyte (ACEA Bio-
sciences) or LSRII (Becton Dickinson) and were analyzed with FlowJo software (TreeStar).
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Cell purification and culture
Total T cells or naive CD4+ T cells were enriched from spleens and lymph nodes by negative selec-
tion using MACS systems (Miltenyi Biotec, Auburn, CA) following the manufacturer’s instructions.
Freshly isolated total T cells with 75-80% CD3 positivity were either maintained in culture media with
5ng/ml IL7 or were stimulated with IL-2 (100U/ml) and plate-bound anti-CD3 (clone 145-2C11) and
anti-CD28 (clone 37.51). Plates were pre-coated with 2 mg/ml antibodies overnight at 4˚C. Cells
were cultured in RPMI 1640 media supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 mg/ml strep-
tomycin at 37 ˚C in 5% CO2. For CFSE dilution analysis, cells were pre-incubated for 10 min in 4 mM
CFSE (Invitrogen) in PBS plus 5% FBS before culture. For iTreg cell differentiation, 0.5 x10
6 naive
CD4+ T cells were stained with 4 mM CFSE and cultured with 100 U/ml IL-2, 5ng/ml TGF-b and
20ng/ml IL-6 in 0.5ml RPMI-1640 media (containing 10% (v/v) heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 mg/ml strep-
tomycin) in 48-well tissue culture plate that was pre-coated with 10mg/ml anti-CD3 and 10mg/ml
anti-CD28 overnight at 4˚C . For TH17 conditions, 0.5 x106 naive CD4+ T cells and 5 x106 irradiated
splenocytes (artificial APC) were cultured with 2 mg/ml anti-CD3 (2C11; Bio X Cell), 2 mg/ml anti-
CD28 (37.51; Bio X Cell), 8 mg/ml anti–IL-2, 8 mg/ml anti–IL-4, 8 mg/ml anti–IFN-g, 2 ng/ml TGF-b,
and 20-50ng/ml IL-6 in 1ml IMDM media (containing 15% (v/v) heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin and 100 mg/ml strep-
tomycin) in 24-well tissue culture plate). For metabolic starvation experiment, Glucose or Glutamine-
free IMDM and RPMI-1640 medium was supplemented with 10% (v/v) heat-inactivated dialyzed fetal
bovine serum (DFBS). For TH17 rescue experiments, 0.5 x10
6 naive CD4+ T cells were activated in
complete IMDM medium. After 24 h cells were switched to conditional glutamine-free IMDM
medium for 4 days. DFBS was made dialyzing against 100 volumes of distilled water (six changes in
three days) using Slide-ALyzer G2 dialysis cassettes with cut-through MW size 2K (ThermoFisher Sci-
entific) at 40C.
qPCR and immunoblot analysis.
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and was reverse transcribed using ran-
dom hexamer and M-MLV Reverse Transcriptase (Invitrogen). SYBR green-based quantitative RT-
PCR was performed using the Applied Biosystems 7900 Real Time PCR System. The relative gene
expression was determined by the comparative CT method also referred to as the 2
 DDC
T method.
The data were presented as the fold change in gene expression normalized to an internal reference
gene (beta2-microglobulin) and relative to the control (the first sample in the group). Fold
change=2 DDCT=[(CTgene of interst- CTinternal reference)]sample A-=[(CTgene of interst- CTinternal reference)]sam-
ple B. Samples for each experimental condition were run in triplicated PCR reactions. Primer sequen-
ces were obtained from Primer Bank (Spandidos et al., 2010). Primer sequences are listed in
Supplementary file 1. Cell extracts were prepared and immunoblotted as previously described
(Wang et al., 2011).
MOG immunization and EAE
Mice were immunized with 100 mg of myelin oligodendrocyte glycoprotein (MOG)35–55 peptide in
CFA (Difco) with 500 mg of Mycobacterium tuberculosis (Difco). Mice were i.p. injected 200 ng of
pertussis toxin (List Biological,#181) on the day of immunization and 2 days later, as described
(Kang et al., 2010). The mice were observed daily for clinical signs and scored as described previ-
ously (Shi et al., 2011).
Histopathology and immunohistochemistry
Mice were euthanized and then were perfused with 25 ml PBS with 2 mM EDTA by heart puncture
to remove blood from internal organs. Spinal cords were taken out and fixed by immersion with 10%
neutral buffered formalin solution and decalcified. Spinal column was divided into cervical, thoracic
and lumbar, and then was embedded in paraffin, sectioned, and stained with standard histological
methods for hematoxylin and eosin (H and E). Immunohistochemistry were performed on serial histo-
logical sections according to standard protocols using anti-Mac2 and anti-CD3 (1:50, Santa Cruz).
Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies were used and
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detected using 3,3’-diaminobenzidine tetrahydrochloride (DAB). Slides were counterstained with
hematoxylin. Microscopy images were taken using Zeiss Axio Scope A1.
Metabolic activity analysis
Glutamine oxidation activity was determined by the rate of 14CO2 released from [U-
14C]-glutamine
(Brand et al., 1984). In brief, one-five million T cells were suspended in 0.5 ml fresh media. To facili-
tate the collection of 14CO2, cells were dispensed into 7 ml glass vials (TS-13028, Thermo) with a
PCR tube containing 50 ml 0.2M KOH glued on the sidewall. After adding 0.5 mci [U-14C]-glutamine,
the vials were capped using a screw cap with rubber septum (TS-12713, Thermo). The assay was
stopped 2 hr later by injection of 100 ml 5N HCL and the vials were kept at room temperate over-
night to trap the 14CO2. The 50 ml KOH in the PCR tube was then transferred to scintillation vials
containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 mci [U-14C]-glu-
tamine was included as a background control.
Pyruvate oxidation activity was determined by the rate of 14CO2 released from [2-
14C]-pyruvate
(Willems et al., 1978). In brief, one to five million T cells were suspended in 0.5 ml fresh T cell
media. To facilitate the collection of 14CO2, cells were dispensed into 7 ml glass vials (TS-13028,
Thermo) with a PCR tube containing 50 ml 0.2M KOH glued on the sidewall. After adding 0.5 mci
[2-14C]-pyruvate, the vials were capped using a screw cap with rubber septum (TS-12713, Thermo).
The assay was stopped 2 hr later by injection of 100 ml 5N HCL and the vials were kept at room tem-
perate overnight to trap the 14CO2. The 50 ml KOH in PCR tube was then transferred to scintillation
vials containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 mci [2-14C]-
pyruvate was included as a background control.
Metabolite extraction and analysis by ion chromatography-ultra high
resolution-Fourier transform mass spectrometry (IC-UHR-FTMS)
Cells were cultured in glutamine-free media with 2 mM 13C5
15N2-glutamine (Cambridge Isotope Lab-
oratories) for 24 hr at 37˚C and were then washed three times in cold PBS before snap freezing. The
frozen cell pellets were homogenized in 60% cold CH3CN in a ball mill (Precellys- 24, Bertin Technol-
ogies) for denaturing proteins and optimizing extraction. Polar metabolites were extracted by the
solvent partitioning method with a final CH3CN:H2O:CHCl3 (2:1.5:1, v/v) ratio, as described previ-
ously (Fan et al., 2012). The polar extracts were lyophilized before reconstitution in nanopure water
and analysis on a Dionex ICS-5000 +ion chromatography interfaced to a Thermo Fusion Orbitrap Tri-
brid mass spectrometer (Thermo Fisher Scientific) as previously described (Fan et al., 2016) using a
m/z scan range of 80–700. Peak areas were integrated and exported to Excel via the Thermo Trace-
Finder (version 3.3) software package before natural abundance correction (Moseley, 2010). The
isotopologue distributions of metabolites were calculated as the mole fractions as previously
described (Lane et al., 2008). The number of moles of each metabolite was determined by calibrat-
ing the natural abundance-corrected signal against that of authentic external standards. The amount
was normalized to the amount of extracted protein, and is reported in mmol/g protein. Metabolome
quantification of GSH and GSSG were determined by CE-MS that was carried out through a facility
service at Human Metabolome Technology Inc., Tsuruoka, Japan.
Statistical analysis
P values were calculated with Student’s t-test all experiment except EAE experiments, where two
way anova test was performed. P values smaller than 0.05 were considered significant, with p-val-
ues<0.05, p-values<0.01, and p-values<0.001 indicated as *, **, and ***, respectively.
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